应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
03692 翰森制药
未开盘 01-16 16:08:38
16.720
+0.020
+0.12%
最高
17.080
最低
16.640
成交量
314.10万
今开
16.820
昨收
16.700
日振幅
2.63%
总市值
992.44亿
流通市值
992.44亿
总股本
59.36亿
成交额
5,272万
换手率
0.05%
流通股本
59.36亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）
资讯
新帖
简况
工银国际给予翰森制药买进的初始评级，目标价22.10港元。给予京东健康中性的初始评级，目标价30.40港元。给予信达生物买进的初始评级，目标价54.80港元。
金融界 · 01-14 19:12
工银国际给予翰森制药买进的初始评级，目标价22.10港元。给予京东健康中性的初始评级，目标价30.40港元。给予信达生物买进的初始评级，目标价54.80港元。
翰森制药01月14日主力资金流入72万元 连续3日加仓
市场透视 · 01-14 16:16
翰森制药01月14日主力资金流入72万元 连续3日加仓
港股开盘向好 恒指高开0.45% 翰森制药(03692)涨3.03%
金吾财讯 · 01-10
港股开盘向好 恒指高开0.45% 翰森制药(03692)涨3.03%
港股开盘，恒指开涨0.45%，科指开涨0.54%。科网股涨跌不一，翰森制药(03692.HK)涨超3%，网易(09999.
美港电讯 · 01-10
港股开盘，恒指开涨0.45%，科指开涨0.54%。科网股涨跌不一，翰森制药(03692.HK)涨超3%，网易(09999.
翰森制药现涨逾3% B7-H3靶向抗体药物偶联物HS-20093获FDA突破性疗法认定
新浪港股 · 01-09
翰森制药现涨逾3% B7-H3靶向抗体药物偶联物HS-20093获FDA突破性疗法认定
港股异动 | 翰森制药(03692)涨超3% B7-H3靶向抗体药物偶联物HS-20093获FDA突破性疗法认定
智通财经 · 01-09
港股异动 | 翰森制药(03692)涨超3% B7-H3靶向抗体药物偶联物HS-20093获FDA突破性疗法认定
智通港股早知道 | 工信部开展万兆光网试点工作 蜜雪冰城港股IPO获备案
智通财经 · 01-08
智通港股早知道 | 工信部开展万兆光网试点工作 蜜雪冰城港股IPO获备案
翰森制药(03692.HK)偶联物HS-20093获FDA突破性疗法认定
阿斯达克财经 · 01-07
翰森制药(03692.HK)偶联物HS-20093获FDA突破性疗法认定
翰森制药(03692)：B7-H3靶向抗体药物偶联物HS-20093用于后线复发或难治性骨肉瘤获FDA突破性疗法认定
智通财经 · 01-07
翰森制药(03692)：B7-H3靶向抗体药物偶联物HS-20093用于后线复发或难治性骨肉瘤获FDA突破性疗法认定
翰森制药01月07日主力资金流入336万元 连续3日加仓
市场透视 · 01-07
翰森制药01月07日主力资金流入336万元 连续3日加仓
生物科技的2024年：“暖意”显现，但仍未越过“寒冬”
财华社 · 01-06
生物科技的2024年：“暖意”显现，但仍未越过“寒冬”
《大行》花旗：“一企一策”显示将为创新领导企业分配资源 翰森制药(03692.HK)及微创医疗(00853.HK)等受惠
阿斯达克财经 · 01-06
《大行》花旗：“一企一策”显示将为创新领导企业分配资源 翰森制药(03692.HK)及微创医疗(00853.HK)等受惠
翰森制药早盘涨逾3% 机构料公司未来两年或迎来创新催化浪潮
新浪港股 · 01-03
翰森制药早盘涨逾3% 机构料公司未来两年或迎来创新催化浪潮
港股异动 | 翰森制药(03692)涨超3% 公司底层创新实力逐步验证 未来两年或迎来创新催化浪潮
智通财经网 · 01-03
港股异动 | 翰森制药(03692)涨超3% 公司底层创新实力逐步验证 未来两年或迎来创新催化浪潮
刚过去的2024，什么行业在闷声发财?
市场投研资讯 · 01-01
刚过去的2024，什么行业在闷声发财?
【券商聚焦】华泰证券首予翰森制药(03692)“买入”评级 目标价22.28港元
金吾财讯 · 2024-12-30
【券商聚焦】华泰证券首予翰森制药(03692)“买入”评级 目标价22.28港元
【药企积极布局新赛道 聚焦三大研发方向】近期，国内药企在GLP-1领域进展消息不断。仿制药方面，12月24日，翰宇药业宣布，公司利拉鲁肽注射液正式登陆美国市场。创新药方面，12月18日，翰森制药宣布，公司授予默沙东口服GLP-1受体激动剂HS-10535全球独家许可权。此外，华东医药、甘李药业、恒瑞医药、通化东宝等多家上市公司亦于12月披露GLP-1领域研发进展。业内人士表示，在火热的GLP-1赛道，海外巨头业绩持续超预期，国内研发进展加速，长效化、多靶点和口服药物研发是目前GLP-1赛道主要研发方向。从GLP-1产业链看，产业链中游和上游有望直接受益于全球多肽药物需求增长，下游的制剂厂商将分享最大的产业链价值。创新药方面，GLP-1市场仍处在蓝海阶段，疗效和上市进度是关键。
金融界 · 2024-12-27
【药企积极布局新赛道 聚焦三大研发方向】近期，国内药企在GLP-1领域进展消息不断。仿制药方面，12月24日，翰宇药业宣布，公司利拉鲁肽注射液正式登陆美国市场。创新药方面，12月18日，翰森制药宣布，公司授予默沙东口服GLP-1受体激动剂HS-10535全球独家许可权。此外，华东医药、甘李药业、恒瑞医药、通化东宝等多家上市公司亦于12月披露GLP-1领域研发进展。业内人士表示，在火热的GLP-1赛道，海外巨头业绩持续超预期，国内研发进展加速，长效化、多靶点和口服药物研发是目前GLP-1赛道主要研发方向。从GLP-1产业链看，产业链中游和上游有望直接受益于全球多肽药物需求增长，下游的制剂厂商将分享最大的产业链价值。创新药方面，GLP-1市场仍处在蓝海阶段，疗效和上市进度是关键。
翰森制药：口服GLP-1授权MSD BD战略再下一城
中金公司 · 2024-12-26
翰森制药：口服GLP-1授权MSD BD战略再下一城
西部证券：多项靶点临床试验进展积极 IgA肾病新药步入收获期
智通财经 · 2024-12-24
西部证券：多项靶点临床试验进展积极 IgA肾病新药步入收获期
中证海外内地股医药卫生指数报1056.95点，前十大权重包含翰森制药等
金融界 · 2024-12-24
中证海外内地股医药卫生指数报1056.95点，前十大权重包含翰森制药等
加载更多
公司概况
公司名称：
翰森制药
所属市场：
SEHK
上市日期：
--
主营业务：
翰森制药集团有限公司是一家主要从事药品研发、生产及销售业务的中国投资控股公司。该公司的主要产品包括欧兰宁、阿美宁、普来乐、泽菲、昕维、昕美、泽坦、迈灵达、恒捷、恒森、孚来迪和瑞波特等。该公司产品主要用于中枢神经系统疾病、抗肿瘤、抗感染、糖尿病、消化道和心血管治疗。该公司主要在中国内地销售产品。
发行价格：
--
{"stockData":{"symbol":"03692","market":"HK","secType":"STK","nameCN":"翰森制药","latestPrice":16.72,"timestamp":1737014918033,"preClose":16.7,"halted":0,"volume":3140950,"delay":0,"floatShares":5935650070,"shares":5935650070,"eps":0.5863694369772766,"marketStatus":"未开盘","change":0.02,"latestTime":"01-16 16:08:38","open":16.82,"high":17.08,"low":16.64,"amount":52723156,"amplitude":0.026347,"askPrice":16.72,"askSize":8000,"bidPrice":16.7,"bidSize":58000,"shortable":3,"etf":0,"ttmEps":0.8034667070568628,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1737077400000},"marketStatusCode":0,"adr":0,"listingDate":1560441600000,"exchange":"SEHK","adjPreClose":16.7,"dividendRate":0.019963,"openAndCloseTimeList":[[1736991000000,1737000000000],[1737003600000,1737014400000]],"volumeRatio":0.711513108688131,"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/03692","defaultTab":"news","newsList":[{"id":"2503523029","title":"工银国际给予翰森制药买进的初始评级，目标价22.10港元。给予京东健康中性的初始评级，目标价30.40港元。给予信达生物买进的初始评级，目标价54.80港元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2503523029","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503523029?lang=zh_cn&edition=full","pubTime":"2025-01-14 19:12","pubTimestamp":1736853147,"startTime":"0","endTime":"0","summary":"工银国际给予翰森制药买进的初始评级，目标价22.10港元。给予京东健康中性的初始评级，目标价30.40港元。给予信达生物买进的初始评级，目标价54.80港元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/14191247444859.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["06618","01801","03692"],"gpt_icon":0},{"id":"2503506185","title":"翰森制药01月14日主力资金流入72万元 连续3日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2503506185","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503506185?lang=zh_cn&edition=full","pubTime":"2025-01-14 16:16","pubTimestamp":1736842586,"startTime":"0","endTime":"0","summary":"01月14日, 翰森制药股价涨2.34%，报收16.64元，成交金额7223万元，换手率0.07%，振幅3.57%，量比0.76。翰森制药今日主力资金净流入72万元，连续3日净流入，上一交易日主力净流入360万元，今日环比减少80.00%。近一年数据显示，该股主力连续3日净流入后，次日上涨概率为52.94%，平均涨幅为2.14%。该股近5个交易日上涨3.31%，主力资金累计净流入698万元，其中2个交易日为股价下跌时净流入；近20日主力资金累计净流入630万元，其中净流入天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250114161704a2215156&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250114161704a2215156&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1589","BK1191","03692","BK1583"],"gpt_icon":0},{"id":"2502088760","title":"港股开盘向好 恒指高开0.45% 翰森制药(03692)涨3.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2502088760","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2502088760?lang=zh_cn&edition=full","pubTime":"2025-01-10 09:26","pubTimestamp":1736472405,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股开盘向好，恒指高开0.45%，国企指数高开0.47%，恒生科技指数高开0.54%。翰森制药涨3.03%，药明生物涨2.25%，紫金矿业涨2.18%，新奥能源涨1.84%。微盟集团低开14.78%，公司宣布，股东腾讯控股于1月3日及6日在公开市场合共完成出售1.84亿股股份，占已发行股份总数约5.45%。十月稻田低开3.1%，公司宣布，联交所已于1月9日授出上市批准及准许买卖165,518,980股H股。内地股市昨日下跌，沪综指低开低走，收市下跌0.6%，沪深两市成交额亦有所缩减。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250106/NDdkYmY2NGUzZGQ4YzY5MzkwZTM0MzQwMzk2Mjg3Mzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/NDdkYmY2NGUzZGQ4YzY5MzkwZTM0MzQwMzk2Mjg3Mzc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1951143","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MHImain","HSCEI","YANG","HSI","513600","HSImain","07226","BK1583","HHImain","BK1191","02833","03692","BK1589","HSTECH","MCHmain"],"gpt_icon":0},{"id":"2502407059","title":"港股开盘，恒指开涨0.45%，科指开涨0.54%。科网股涨跌不一，翰森制药(03692.HK)涨超3%，网易(09999.","url":"https://stock-news.laohu8.com/highlight/detail?id=2502407059","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2502407059?lang=zh_cn&edition=full","pubTime":"2025-01-10 09:21","pubTimestamp":1736472081,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["HK0000306701.USD","SG9999004220.SGD","IE00B3T34201.USD","MHImain","02833","HK0000306685.HKD","07226","09999","NTES","LU1363072403.SGD","SGXZ23171101.USD","LU0048597586.USD","HSI","81299","LU1481012133.USD","LU2087589342.USD","LU0594300179.USD","LU0417516738.SGD","LU1046422090.SGD","LU0762540952.USD","SG9999001903.USD","LU1328277881.USD","SG9999002562.SGD","LU0828237940.HKD","LU1226287529.USD","AAGIY","LU0228367735.SGD","LU0862451753.SGD","LU0898667661.SGD","LU0886674414.USD","LU0106959298.USD","LU1794554557.SGD","LU0572940350.SGD","LU0630378692.HKD","513600","LU0269904917.USD","LU0164880469.USD","LU1044874839.SGD","03692","MCHmain","HSImain","HSCEI","LU2242644610.SGD","YANG","LU0414403682.SGD","01299","HSTECH","HHImain","HK0000320223.HKD","LU0096374516.USD"],"gpt_icon":0},{"id":"2502662037","title":"翰森制药现涨逾3% B7-H3靶向抗体药物偶联物HS-20093获FDA突破性疗法认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2502662037","media":"新浪港股","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2502662037?lang=zh_cn&edition=full","pubTime":"2025-01-09 10:13","pubTimestamp":1736388780,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n 翰森制药（03692）早盘上涨2.84%，现报16.68港元，成交额1482.02万港元。\n 1月7日，翰森制药公布，GSK就GSK5764227（GSK’227，亦称 HS-20093）获美国食品药品监督管理局（FDA）授予突破性疗法认定（BTD），此B7-H3靶向抗体药物偶联物（ADC）正在评估用于治疗既往经二线及以上治疗进展的复发或难治性骨肉瘤（骨癌）成人患者。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-01-09/doc-ineeitpf3328807.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["03692","BK1583","BK1191","BK1589"],"gpt_icon":0},{"id":"2502103220","title":"港股异动 | 翰森制药(03692)涨超3% B7-H3靶向抗体药物偶联物HS-20093获FDA突破性疗法认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2502103220","media":"智通财经","labels":["productRelease","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2502103220?lang=zh_cn&edition=full","pubTime":"2025-01-09 10:03","pubTimestamp":1736388199,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，翰森制药涨超3%，截至发稿，涨3.33%，报16.76港元，成交额1134.24万港元。消息面上，1月7日，翰森制药公布，GSK就GSK5764227获美国食品药品监督管理局授予突破性疗法认定，此B7-H3靶向抗体药物偶联物正在评估用于治疗既往经二线及以上治疗进展的复发或难治性骨肉瘤(骨癌)成人患者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1235289.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"港股异动 | 翰森制药(03692)涨超3% B7-H3靶向抗体药物偶联物HS-20093获FDA突破性疗法认定","news_tag":"productRelease,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03692","BK1589","BK1191","BK1583"],"gpt_icon":0},{"id":"2501675248","title":"智通港股早知道 | 工信部开展万兆光网试点工作 蜜雪冰城港股IPO获备案","url":"https://stock-news.laohu8.com/highlight/detail?id=2501675248","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2501675248?lang=zh_cn&edition=full","pubTime":"2025-01-08 07:41","pubTimestamp":1736293288,"startTime":"0","endTime":"0","summary":"工业和信息化部办公厅：开展万兆光网试点工作通知提出，到2025年底，在有条件、有基础的城市和地区，聚焦小区、工厂、园区等重点场景，开展万兆光网试点。其中提出，开展“万兆工厂”试点。根据该通知，美国国防部副部长已将公司列入中国军工企业名单。蜜雪冰城港股IPO获中国证监会备案中国证监会国际合作司1月7日发布关于蜜雪冰城股份有限公司首次公开发行境外上市外资股及境内未上市股份“全流通”的备案通知书。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1234652.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0315178854.USD","SG9999014880.SGD","LU0737861699.HKD","SG9999001093.SGD","IE00B3M56506.USD","LU0235996351.USD","HSCEI","LU0865486749.SGD","YANG","LU0327786744.USD","03692","LU0561508036.HKD","LU0414403682.SGD","LU0049853897.USD","LU0469268626.HKD","HTCD.SI","01833","SGXZ31699556.SGD","LU0455707207.USD","LU0642271901.SGD","00700","LU0878005551.USD","LU2039709279.SGD","LU0572944931.SGD","SG9999001689.USD","TCEHY","BK1516","LU1044876610.USD","BK1205","01072","LU1323998911.USD","IE00B29SXG58.USD","IE00BZ08YS42.EUR","LU0541501648.USD","LU2251237306.USD","LU0196878994.USD","LU0700851271.USD","IE0008368411.USD","07226","BK1517","HSTECH","LU0096374516.USD","LU1282649810.SGD","BK1219","SG9999000418.SGD","SG9999014898.SGD","80700","SG9999014914.USD","LU0823413587.USD","LU0871576103.HKD"],"gpt_icon":1},{"id":"2501939785","title":"翰森制药(03692.HK)偶联物HS-20093获FDA突破性疗法认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2501939785","media":"阿斯达克财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2501939785?lang=zh_cn&edition=full","pubTime":"2025-01-07 23:02","pubTimestamp":1736262120,"startTime":"0","endTime":"0","summary":"翰森制药(03692.HK) 公布，GlaxoSmithKline“GSK”就GSK5764227(亦称HS-20093)获美国食品药品监督管理局“FDA”授予突破性疗法认定，此B7-H3靶向抗体药物偶联物正在评估用于治疗既往经二线及以上治疗进展的复发或难治性骨癌成人患者。2023年12月，集团与GSK订立协议，据此GSK获授予全球独占许可以开发、生产及商业化HS-20093。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-01-07 16:25。)AASTOCKS新闻","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20191009132908649_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20191009132908649_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1408575/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1589","BK1191","03692","BK1583"],"gpt_icon":0},{"id":"2501274631","title":"翰森制药(03692)：B7-H3靶向抗体药物偶联物HS-20093用于后线复发或难治性骨肉瘤获FDA突破性疗法认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2501274631","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2501274631?lang=zh_cn&edition=full","pubTime":"2025-01-07 19:17","pubTimestamp":1736248666,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰森制药(03692)公布，GSK就GSK5764227(GSK’227，亦称 HS-20093)获美国食品药品监督管理局(FDA)授予突破性疗法认定(BTD)，此B7-H3靶向抗体药物偶联物(ADC)正在评估用于治疗既往经二线及以上治疗进展的复发或难治性骨肉瘤(骨癌)成人患者。HS-20093是一种新型B7-H3靶向ADC，由全人源抗B7-H3单抗与拓扑异构酶抑制剂(TOPOi)有效载荷共价连接而成，正于中国开展用于治疗肺癌、肉瘤、头颈癌以及其他实体瘤的多项I期、II期及III期临床研究。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1234513.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"翰森制药(03692)：B7-H3靶向抗体药物偶联物HS-20093用于后线复发或难治性骨肉瘤获FDA突破性疗法认定","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1589","03692","BK1583","BK1191"],"gpt_icon":0},{"id":"2501224745","title":"翰森制药01月07日主力资金流入336万元 连续3日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2501224745","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2501224745?lang=zh_cn&edition=full","pubTime":"2025-01-07 16:15","pubTimestamp":1736237745,"startTime":"0","endTime":"0","summary":"01月07日, 翰森制药股价跌1.57%，报收16.32元，成交金额1.05亿元，换手率0.11%，振幅3.74%，量比1.17。翰森制药今日主力资金净流入336万元，连续3日净流入，上一交易日主力净流入138万元，今日环比增加143.48%。近一年数据显示，该股主力连续3日净流入后，次日上涨概率为52.94%，平均涨幅为2.14%。该股近5个交易日下跌6.32%，主力资金累计净流入423万元；近20日主力资金累计净流入102万元，其中净流入天数为6日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250107161609a2188d1f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250107161609a2188d1f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","03692","BK1589","BK1191"],"gpt_icon":0},{"id":"2501217470","title":"生物科技的2024年：“暖意”显现，但仍未越过“寒冬”","url":"https://stock-news.laohu8.com/highlight/detail?id=2501217470","media":"财华社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2501217470?lang=zh_cn&edition=full","pubTime":"2025-01-06 14:01","pubTimestamp":1736143306,"startTime":"0","endTime":"0","summary":"经历2023年生物科技行业的资本寒冬之后，2024年该行业迎来了复苏阶段。尤其是在政策暖风及美联储降息周期打开之下，市场预期迎来破冰，不少生物科技股迎来上涨。","market":"us","thumbnail":"https://images.finet.hk/photoLib/title/202501_1/c4714887-4bde-407a-8eff-77c211894be0.png","type":0,"news_type":0,"thumbnails":["https://images.finet.hk/photoLib/title/202501_1/c4714887-4bde-407a-8eff-77c211894be0.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.finet.hk/newscenter/news_content/677b71ca2308293c5d837142","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"finet_stock","symbols":["BK1161","LU0588546209.SGD","01952","LU0348783233.USD","BK1191","BK1500","01672","06855","LU0307460666.USD","BK1574","02105","02410","LU2328871848.SGD","LU0417516571.SGD","LU1794554557.SGD","06160","IE00B543WZ88.USD","LU2488822045.USD","BK1583","IE00B5MMRT66.SGD","01228","LU1720050803.USD","03692","IE00BPRC5H50.USD","09926","BK1588","BK1589","LU1969619763.USD","LU0348784397.USD","BK1515"],"gpt_icon":0},{"id":"2501763654","title":"《大行》花旗：“一企一策”显示将为创新领导企业分配资源 翰森制药(03692.HK)及微创医疗(00853.HK)等受惠","url":"https://stock-news.laohu8.com/highlight/detail?id=2501763654","media":"阿斯达克财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2501763654?lang=zh_cn&edition=full","pubTime":"2025-01-06 11:13","pubTimestamp":1736133180,"startTime":"0","endTime":"0","summary":"更快的生物等效性测试应有利仿制药生产商如中生制药及石四药。该行料相关股份短期有支持。沽空资料截至 2025-01-03 16:25。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180125102134442_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180125102134442_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1408044/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1589","BK1585","03692","BK1583","00853","BK1191","BK1100"],"gpt_icon":0},{"id":"2500133066","title":"翰森制药早盘涨逾3% 机构料公司未来两年或迎来创新催化浪潮","url":"https://stock-news.laohu8.com/highlight/detail?id=2500133066","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2500133066?lang=zh_cn&edition=full","pubTime":"2025-01-03 09:40","pubTimestamp":1735868400,"startTime":"0","endTime":"0","summary":" 翰森制药盘中涨超3%，截至发稿，股价上涨2.52%，现报17.10港元，成交额1263.38万港元。 华泰证券发布研报指出，翰森制药是国内创新转型较为成功的综合性药企之一，合计拥有8个已上市创新药，数量居国内药企第2，8款已上市创新药获批进度均为国内同类品种前二，且在疗效、安全性等方面均较竞品具备优势，底层创新实力逐步验证，未来两年或迎来创新催化浪潮。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-01-03/doc-inecsexf1657364.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1191","BK1589","BK1583","03692"],"gpt_icon":0},{"id":"2500138421","title":"港股异动 | 翰森制药(03692)涨超3% 公司底层创新实力逐步验证 未来两年或迎来创新催化浪潮","url":"https://stock-news.laohu8.com/highlight/detail?id=2500138421","media":"智通财经网","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2500138421?lang=zh_cn&edition=full","pubTime":"2025-01-03 09:33","pubTimestamp":1735868011,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，翰森制药涨超3%，截至发稿，涨3.48%，报17.26港元，成交额801.53万港元。华泰证券发布研报指出，翰森制药是国内创新转型较为成功的综合性药企之一，合计拥有8个已上市创新药，数量居国内药企第2，8款已上市创新药获批进度均为国内同类品种前二，且在疗效、安全性等方面均较竞品具备优势，底层创新实力逐步验证，未来两年或迎来创新催化浪潮。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1232911.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1583","BK1191","BK1589","03692"],"gpt_icon":0},{"id":"2500671791","title":"刚过去的2024，什么行业在闷声发财?","url":"https://stock-news.laohu8.com/highlight/detail?id=2500671791","media":"市场投研资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2500671791?lang=zh_cn&edition=full","pubTime":"2025-01-01 11:34","pubTimestamp":1735702440,"startTime":"0","endTime":"0","summary":" 2024年，大家的经济体感不太好，普遍承压，但依然有些行业在闷声发大财。 妙投对2024年申万二级三级行业即经济体系中的大类行业和细分领域的增长态势做了全面梳理，结合2024年前三季度上市公司的财报，对这些行业的整体增速、不同板块上市公司营收与净利润进行了对比，结果发现——。 2024年前三季度半导体行业实现营收4304.94亿元，同比增长21.63%，实现归母净利润290.29亿元，224.75亿元，同比提升23.53%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-01-01/doc-inecmssw9706618.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0188","BK1515","LU1969619763.USD","600276","BK1521","BK0060","LU1064131003.USD","BK0239","BMS","06978","BK0196","LU2148510915.USD","300558","BK1191","BK1574","BK1589","01177","LU0405327148.USD","LU2328871848.SGD","LU0405327494.USD","BK1583","BK1161","LU1064130708.USD","03692","BK0028","BK0012","BK0183","LU2488822045.USD","002422","LU1328615791.USD"],"gpt_icon":0},{"id":"2495591678","title":"【券商聚焦】华泰证券首予翰森制药(03692)“买入”评级 目标价22.28港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2495591678","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2495591678?lang=zh_cn&edition=full","pubTime":"2024-12-30 15:28","pubTimestamp":1735543725,"startTime":"0","endTime":"0","summary":"该行指，公司是国内创新转型较为成功的综合性药企之一，合计拥有8个已上市创新药，数量居国内药企第2，8款已上市创新药获批进度均为国内同类品种前二，且在疗效、安全性等方面均较竞品具备优势，底层创新实力逐步验证，未来两年或迎来创新催化浪潮。该行预测，公司2024~26年归母净利润为42.36/41.11/37.99亿元。该行给予公司SOTP估值1323亿港币，对应目标价22.28港币。","market":"hk","thumbnail":"https://static.szfiu.com/news/20241108/ZWZlMGNjODY1NzQ4NjMzODA5NjU5ODM=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/ZWZlMGNjODY1NzQ4NjMzODA5NjU5ODM=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1950446","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692","06886"],"gpt_icon":0},{"id":"2494289796","title":"【药企积极布局新赛道 聚焦三大研发方向】近期，国内药企在GLP-1领域进展消息不断。仿制药方面，12月24日，翰宇药业宣布，公司利拉鲁肽注射液正式登陆美国市场。创新药方面，12月18日，翰森制药宣布，公司授予默沙东口服GLP-1受体激动剂HS-10535全球独家许可权。此外，华东医药、甘李药业、恒瑞医药、通化东宝等多家上市公司亦于12月披露GLP-1领域研发进展。业内人士表示，在火热的GLP-1赛道，海外巨头业绩持续超预期，国内研发进展加速，长效化、多靶点和口服药物研发是目前GLP-1赛道主要研发方向。从GLP-1产业链看，产业链中游和上游有望直接受益于全球多肽药物需求增长，下游的制剂厂商将分享最大的产业链价值。创新药方面，GLP-1市场仍处在蓝海阶段，疗效和上市进度是关键。","url":"https://stock-news.laohu8.com/highlight/detail?id=2494289796","media":"金融界","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2494289796?lang=zh_cn&edition=full","pubTime":"2024-12-27 04:44","pubTimestamp":1735245849,"startTime":"0","endTime":"0","summary":"仿制药方面，12月24日，翰宇药业宣布，公司利拉鲁肽注射液正式登陆美国市场。业内人士表示，在火热的GLP-1赛道，海外巨头业绩持续超预期，国内研发进展加速，长效化、多靶点和口服药物研发是目前GLP-1赛道主要研发方向。从GLP-1产业链看，产业链中游和上游有望直接受益于全球多肽药物需求增长，下游的制剂厂商将分享最大的产业链价值。创新药方面，GLP-1市场仍处在蓝海阶段，疗效和上市进度是关键。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2024/12/27044446869434.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0239","SG9999001176.SGD","600867","LU1066051811.HKD","IE00BJT1NW94.SGD","LU0965509101.SGD","LU1699723380.USD","LU1917777945.USD","LU1934455194.USD","IE00B1BXHZ80.USD","LU1585245621.USD","LU1116320901.HKD","SG9999015341.SGD","LU1066051498.USD","LU0861579265.USD","159992","SG9999014567.USD","06978","BK1589","IE00BBT3K403.USD","LU1934455863.HKD","LU1037948897.HKD","SG9999002232.USD","BK4533","MRK","IE00BN8TJ469.HKD","BK1583","LU1328615791.USD","BK0187","300199","03692","LU0122379950.USD","LU0211331839.USD","IE00BLSP4452.SGD","GLP","SG9999014559.SGD","IE00BFTCPJ56.SGD","LU1934455277.USD","LU1064130708.USD","000963","LU1989772840.SGD","LU2461242641.AUD","SG9999015358.SGD","600276","LU1064131003.USD","LU0238689110.USD","BK4516","LU1974910355.USD","LU0405327494.USD","603087"],"gpt_icon":0},{"id":"2494053450","title":"翰森制药：口服GLP-1授权MSD BD战略再下一城","url":"https://stock-news.laohu8.com/highlight/detail?id=2494053450","media":"中金公司","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2494053450?lang=zh_cn&edition=full","pubTime":"2024-12-26 00:00","pubTimestamp":1735142400,"startTime":"0","endTime":"0","summary":"公司近况2024 年12 月18 日，公司公告授予默沙东HS-10535全球独家许可协议。评论与MSD达成GLP-1 合作，交易总额超20 亿美元。多款GLP-1 产品布局，在国内企业中进度居前。公司在GLP-1 领域布局了聚乙二醇洛塞那肽注射液，HS-20094，HS-10501，以及本次授权的HS-10535。我们认为此次合作代表了MSD对公司GLP-1 研发能力的高度认可。截至目前，公司累计BD项目超20 个，更是通过海外授权的方式加速出海。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241226074240a2099d65&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241226074240a2099d65&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","03692","BK1589","BK1191"],"gpt_icon":0},{"id":"2493772415","title":"西部证券：多项靶点临床试验进展积极 IgA肾病新药步入收获期","url":"https://stock-news.laohu8.com/highlight/detail?id=2493772415","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493772415?lang=zh_cn&edition=full","pubTime":"2024-12-24 16:17","pubTimestamp":1735028255,"startTime":"0","endTime":"0","summary":"未来IgA肾病新药均可作为IgA肾病患者一线用药在临床上使用。IgA肾病市场概况西部证券表示，最新的《2024版KDIGO IgA肾病和IgA血管炎临床管理实践指南》不再强调3个月支持治疗观察期。IgA肾病新药临床进展目前多项IgA肾病新药正在开展临床试验，这些新药针对IgA肾病治疗新途径，包括B细胞调节和抑制补体途径。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1228961.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002673","BK1576","BK0188","BK1574","BK1161","BK1589","LU1969619763.USD","LU2328871848.SGD","BK0183","BK1141","01952","09995","03347","03692","BK1583","BK1191","BK0276","BK0028"],"gpt_icon":0},{"id":"2493779489","title":"中证海外内地股医药卫生指数报1056.95点，前十大权重包含翰森制药等","url":"https://stock-news.laohu8.com/highlight/detail?id=2493779489","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493779489?lang=zh_cn&edition=full","pubTime":"2024-12-24 15:27","pubTimestamp":1735025243,"startTime":"0","endTime":"0","summary":"金融界12月24日消息，上证指数高开高走，中证海外内地股医药卫生指数 报1056.95点。数据统计显示，中证海外内地股医药卫生指数近一个月上涨1.54%，近三个月上涨6.32%，年至今下跌16.93%。该指数以2004年12月31日为基日，以1000.0点为基点。从中证海外内地股医药卫生指数持仓样本的行业来看，制药与生物科技服务占比21.66%、药品制剂占比18.75%、医药商业占比11.18%。当对应的母指数调整样本时，行业指数样本将相应调整。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241224153245a206ed2e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241224153245a206ed2e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","BK1191","03692","BK1589"],"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0.0146},{"period":"1month","weight":-0.0596},{"period":"3month","weight":-0.2417},{"period":"6month","weight":-0.0226},{"period":"1year","weight":0.3361},{"period":"ytd","weight":-0.0324}],"compareEarnings":[{"period":"1week","weight":0.0147},{"period":"1month","weight":-0.009},{"period":"3month","weight":-0.0616},{"period":"6month","weight":0.1209},{"period":"1year","weight":0.2779},{"period":"ytd","weight":-0.0268}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"翰森制药集团有限公司是一家主要从事药品研发、生产及销售业务的中国投资控股公司。该公司的主要产品包括欧兰宁、阿美宁、普来乐、泽菲、昕维、昕美、泽坦、迈灵达、恒捷、恒森、孚来迪和瑞波特等。该公司产品主要用于中枢神经系统疾病、抗肿瘤、抗感染、糖尿病、消化道和心血管治疗。该公司主要在中国内地销售产品。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.02582},{"month":2,"riseRate":0.4,"avgChangeRate":-0.000679},{"month":3,"riseRate":0.2,"avgChangeRate":-0.042176},{"month":4,"riseRate":0.6,"avgChangeRate":0.041697},{"month":5,"riseRate":0.6,"avgChangeRate":0.008682},{"month":6,"riseRate":0.6,"avgChangeRate":0.03658},{"month":7,"riseRate":0.5,"avgChangeRate":-0.032646},{"month":8,"riseRate":0.666667,"avgChangeRate":0.018947},{"month":9,"riseRate":0.5,"avgChangeRate":-0.03981},{"month":10,"riseRate":0.166667,"avgChangeRate":0.003801},{"month":11,"riseRate":0.666667,"avgChangeRate":0.052626},{"month":12,"riseRate":0.666667,"avgChangeRate":0.036825}],"exchange":"SEHK","name":"翰森制药","nameEN":"HANSOH PHARMA"},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.30.2","shortVersion":"4.30.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"翰森制药(03692)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供翰森制药(03692)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"翰森制药,03692,翰森制药股票,翰森制药股票老虎,翰森制药股票老虎国际,翰森制药行情,翰森制药股票行情,翰森制药股价,翰森制药股市,翰森制药股票价格,翰森制药股票交易,翰森制药股票购买,翰森制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"翰森制药(03692)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供翰森制药(03692)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}